Innovative Pharmaceutical Products

"Dedicated to Man’s Fight against Disease and Pain" is our corporate philosophy as a pharmaceutical company dedicated to the development of new drugs. In line with this philosophy, we work to bring world-class innovative drugs as soon as possible to patients across the globe through collaboration between all our divisions including research, development, business strategy, manufacturing, safety/quality assurance, and marketing, as well as through the dedication of all employees to the efforts with passion and conviction.


ONO’s mission, policy, and structure regarding research and development are introduced.

Drug development policy


Research structure


Business Strategy

ONO’s licensing activities and major partners are introduced.

Drug discovery alliances


Global business and licensing activities





ONO’s development structure and progress on new drugs being developed are introduced.

Development structure


IR library


*Please refer to the status of development pipeline.

Manufacturing and Safety/Quality Assurance

ONO’s manufacturing and safety/quality assurance initiatives are introduced.

Manufacturing and safety/
quality assurance



ONO’s marketing initiatives and main products are introduced.

Marketing (scientific information)


Main products


Efforts Made for Improving Medical Access

Basic Policy

Even today as we see remarkable development in the medical field, there are many diseases against which no effective treatment exists. Also, in low- and lower middle-income countries, there are many people who have difficulty receiving necessary medical care due to various reasons such as inadequate medical infrastructure and poverty. Under the corporate philosophy “Dedicated to Man’s Fight against Disease and Pain,” we aim to improve the degree of medical access with the following goals: development of innovative pharmaceutical products, improvement of medical infrastructure and the establishment of partnerships with outside parties.

The Direction of our efforts

  • ・Promotion of research and development for measures against diseases for which patients’ medical needs are not yet met, rare diseases, and intractable diseases
  • ・Local medical education, training of medical personnel, improvement of medical supplies in countries and regions where medical infrastructure is not fully developed
  • ・Establishment of partnerships with outside parties as necessary to deal with issues

Promotion Management System

The management team oversees the directions for the improvement of medical access and the details of the efforts.
New efforts associated with medical access will be deliberated on and approved by the CSR Committee, chaired by the Senior Executive Officer. Its activities are periodically reported to the Management Strategy Meeting which is chaired by the CEO.

Examples of Efforts

Working on the treatment of rare diseases is important so as to improve medical access. We make the following efforts to develop and provide pharmaceuticals for rare diseases.

Product name Therapeutic indication Date designated as an orphan drug Status
OPDIVO intravenous infusion Malignant melanoma that has no possibility of radical resection 2013.06.17 Approved
Recurrent or intractable classical Hodgkin lymphoma 2016.03.16 Approved
Progressing or metastatic malignant pleural mesothelioma that has no possibility of radical resection 2017.12.01 Approved
(generic name)
Improvement of pheochromocytoma symptoms in a state of excess catecholamine release and associated improvement of other symptoms 2015.05.25 Under development
Kyprolis for intravenous infusion Recurrent or intractable multiple myeloma 2015.08.20 Approved
Onoact for intravenous infusion The kinds of life-threatening cardiac arrhythmia in intractable and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia 2016.08.24 Under development
(generic name)
Malignant melanoma due to BRAF mutations that has no possibility of radical resection 2018.03.30 Under development
(generic name)
Malignant melanoma due to BRAF mutations that has no possibility of radical resection 2018.03.30 Under development

In addition, Opdivo is designated as a target item under the Priority Assessment Designation System, specified by the Ministry of Health, Labour and Welfare, that targets bile duct cancer.

Efforts Made for Flexible Approval for Children

Medication evaluated appropriately for children should be used for pediatric patients. Aiming to improve pediatric patients’ access to pharmaceuticals, we are working on the flexible approval for children as follows.

Product name Pharmaceutical indication Status
Prostandin for injection Patency of ductus arteriosus in ductus arteriosus-dependent congenital heart disease Approved
Onon® Dry Syrup Bronchial asthma and allergic rhinitis Approved
EMEND® Capsules Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including the delayed phase) Approved
PROEMEND® for intravenous injection. Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including the delayed phase) Approved
Orencia for intravenous infusion Active polyarticular juvenile idiopathic arthritis Approved
Onoact for intravenous infusion Tachyarrhythmia in cases of cardiac function failure Under development

Efforts Made against Intractable Diseases

Together with Keio University, Kochi University, the National Institute of Biomedical Innovation, Health and Nutrition, Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Co., Ltd., we established the Immune-mediated Inflammatory Diseases Consortium for Drug Development for the purpose of drug development research targeting intractable immunoinflammatory diseases in May 2018. It is expected that the achievements of this consortium will lead to the creation of next-generation pharmaceuticals with high utility against intractable immunoinflammatory diseases and also enable the provision of new treatment options for patients and healthcare professionals.


As an effort made to promote both Work Style Reform and activities to contribute to society, we started Project ONO SWITCH in August 2018. This effort is an effort to make donations to NPOs/NGOs related to medical care using the money saved through the reduction of overtime work through the promotion of Work Style Reform, aiming to further promote the embodiment of the corporate philosophy “Dedicated to Man’s Fight against Disease and Pain" by contributing to the promotion of working style reform and healthcare and people’s health around the world.

The project was named by abbreviating Save the World by our work style ImprovemenT and CHange (meaning saving the world through improvement and reform of our ways of working). The project name also expresses switching work methods to new ones, switching the funds obtained through working style reform to donation, and switching on the process of reexamining how to work.

Recipients: We donated to the following NPOs based on responses to questionnaires targeting all our employees.

Partner Description of efforts made Area of operation
1 Nanbyo no Kodomo Shien Zenkoku Network (Nation-wide Network to Support Children with Intractable Disease) (1) To hold symposia aiming to provide information on intractable diseases.
(2) To support camping and other events, which provide opportunities for families with children with intractable disease to interact each other.
2 Vaccines for the World’s Children (1) To provide mixed diphtheria/pertussis/tetanus vaccines and hepatitis B vaccines used in Bhutan throughout the year.
(2) To provide Ice Line coolers for refrigerating the vaccine. Providing the coolers will lead to support for a medium- to long-term vaccine supply.
3 Japan Heart (1) To strengthen the local medical infrastructure in the medium- to long-term by developing medical professionals through multiple-year support for high school students who are from rural regions in Cambodia that aim to become doctors or nurses.
(2) To provide local doctors with education about primary life-saving measures by conducting training programs on initial responses to a sudden deterioration in a patient’s condition, mainly about cardiopulmonary resuscitation, for Cambodian doctors whose knowledge is not sufficient.

In this project, we will work on improving access to pharmaceutical products and improving medical infrastructure through partnerships with outside parties.

Participation in the Global Health Innovative Technology Fund

We became a member company of the Global Health Innovative Technology Fund (GHIT Fund) in 2018. The GHIT Fund is an international, non-profit organization that invests in the development of new drugs against various diseases such as malaria and tuberculosis, other less marketable drugs against neglected tropical diseases and other minor diseases, vaccines, and diagnostic agents, and is funded by the Japanese government, the Bill & Melinda Gates Foundation, the Welcome Trust, and private enterprises in Japan and overseas. In order to reduce the health disparities between developed countries and low- and middle-income countries, the therapeutic agents, vaccines, and diagnostic agents developed through the GHIT Fund's investments are priced according to the “No Gain, No Loss” principle. We understand the efforts and policy, and we contribute to the funding of the GHIT Fund. Through participation in the GHIT Fund, we will strengthen the establishment of partnerships aiming to improve medical access in low- and middle-income countries.